Ifinatamab Deruxtecan Shows Promising Results in Small Cell Lung Cancer Trial
The Phase 2 IDeate-Lung01 trial showed that the drug ifinatamab deruxtecan achieved a 48.2% objective response rate in previously treated extensive-stage small cell lung cancer patients, with promising safety and efficacy data supporting further regulatory discussions.